M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
TxCell enters Col-Treg into Full Development for the rare disease Autoimmune Uveitis; Col-Treg is second product candidate from TxCell's proprietary personalized cellular immunotherapy platform - ASTrIA
Valbonne, France - TxCell SA, a clinical stage biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, today announces it has initiated a full development program...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives